Evidence map›Paper›PMID 36359411›Full record

ArticleDiagnostics (Basel, Switzerland)2022

SARS-CoV-2 IgG Levels Allow Predicting the Optimal Time Span of Convalescent Plasma Donor Suitability.

Sandra Laner-Plamberger, Nadja Lindlbauer, Lisa Weidner, Simon Gänsdorfer, Lukas Weseslindtner, Nina Held, Wanda Lauth, Georg Zimmermann, Jan Marco Kern, Fabian Föttinger and 4 more

Abstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sandra Laner-PlambergerDepartment for Transfusion Medicine, University Hospital of Salzburg, Paracelsus Medical University Salzburg, Müllner-Hauptstraße 48, 5020 Salzburg, Austria.ORCID 0000-0002-1416-6023
Nadja LindlbauerDepartment for Transfusion Medicine, University Hospital of Salzburg, Paracelsus Medical University Salzburg, Müllner-Hauptstraße 48, 5020 Salzburg, Austria.
Lisa WeidnerAustrian Red Cross, Blood Service for Vienna, Lower Austria and Burgenland, Wiedner Hauptstraße 32, 1040 Vienna, Austria.
Simon GänsdorferAustrian Red Cross, Blood Service for Vienna, Lower Austria and Burgenland, Wiedner Hauptstraße 32, 1040 Vienna, Austria.
Lukas WeseslindtnerDepartment for Virology, Medical University Vienna, Kinderspitalgasse 15, 1090 Vienna, Austria.ORCID 0000-0001-8950-937X
Nina HeldDepartment for Transfusion Medicine, University Hospital of Salzburg, Paracelsus Medical University Salzburg, Müllner-Hauptstraße 48, 5020 Salzburg, Austria.
Wanda LauthTeam Biostatistics and Big Medical Data, IDA Lab Salzburg, Paracelsus Medical University Salzburg, Strubergasse 16, 5020 Salzburg, Austria.
Georg ZimmermannTeam Biostatistics and Big Medical Data, IDA Lab Salzburg, Paracelsus Medical University Salzburg, Strubergasse 16, 5020 Salzburg, Austria.ORCID 0000-0002-8282-1034
Jan Marco KernDepartment for Clinical Microbiology and Hygiene, University Hospital of Salzburg, Paracelsus Medical University Salzburg, Müllner-Hauptstraße 48, 5020 Salzburg, Austria.
Fabian FöttingerDepartment for Transfusion Medicine, University Hospital of Salzburg, Paracelsus Medical University Salzburg, Müllner-Hauptstraße 48, 5020 Salzburg, Austria.
Laura OmbresDepartment for Transfusion Medicine, University Hospital of Salzburg, Paracelsus Medical University Salzburg, Müllner-Hauptstraße 48, 5020 Salzburg, Austria.
Christof JungbauerAustrian Red Cross, Blood Service for Vienna, Lower Austria and Burgenland, Wiedner Hauptstraße 32, 1040 Vienna, Austria.
Eva RohdeDepartment for Transfusion Medicine, University Hospital of Salzburg, Paracelsus Medical University Salzburg, Müllner-Hauptstraße 48, 5020 Salzburg, Austria.ORCID 0000-0001-8692-886X
Christoph GrabmerDepartment for Transfusion Medicine, University Hospital of Salzburg, Paracelsus Medical University Salzburg, Müllner-Hauptstraße 48, 5020 Salzburg, Austria.

Funding

WISS 2025 project 'IDA-Lab Salzburg' 20204-WISS/225/197-2019 and 20102-F1901166-KZP
6 · The paper itself

Abstract

Convalescent plasma (CP) has been in use for the treatment of numerous infectious diseases for more than a century, recently also for coronavirus disease 2019 (COVID-19). A major challenge for this treatment is identifying suitable donors with sufficient levels of functional antibodies and to determine the optimal time span for CP donation. In this retrospective study, we analyzed 189 CP donations of 66 donors regarding anti-SARS-CoV-2 anti-S IgG antibody levels. We found a significant correlation between the semi-quantitative SARS-CoV-2 IgG ratio values and in vitro antibody functionality. A time-to-event analysis allowed us to predict the optimal time span of COVID-19 CP donor suitability. We found that high IgG ratio values, which significantly correlate with high in vitro antibody functionality, were suitable for CP donation for a median of 134 days after the first CP donation. Donors with lower IgG ratios were suitable for a median of 53 days. Our data support plasma collection centers to determine optimal points in time for CP donation by means of widely used semi-quantitative laboratory IgG ratio values.

Indexed as

convalescent plasmaCOVID-19plasmapheresisSARS-CoV-2 antibodies

Identifiers

PMID36359411
PMCPMC9689947

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.